Eisai Demonstrates Commitment to Advanced Endometrial Cancer Care at IGCS 2025
PR Newswire —
Five-year survival data from pivotal Phase 3 Study 309/KEYNOTE-775 trial evaluating lenvatinib plus pembrolizumab in certain patients with advanced endometrial carcinoma Efficacy outcomes in patients with advanced endometrial carcinoma who received prior (neo)adjuvant therapy from Phase 3...